Cancer Discov. 2018 Jan;8(1):4-5. doi: 10.1158/2159-8290.CD-NB2017-169. Epub 2017 Dec 5.
After conducting an internal probe of the five deaths that halted JCAR015's development for acute lymphoblastic leukemia, Juno Therapeutics has concluded that multiple factors were at play. A surge in inflammatory cytokine levels from rapid, early T-cell proliferation may have provoked the blood-brain barrier disruption seen in these patients, inducing fatal cerebral edema.
在对导致JCAR015治疗急性淋巴细胞白血病的研发工作暂停的五例死亡病例进行内部调查后，朱诺治疗公司得出结论，多种因素在其中起了作用。早期T细胞快速增殖导致炎症细胞因子水平激增，这可能引发了这些患者出现的血脑屏障破坏，进而诱发致命的脑水肿。
